Synta Pharmaceuticals, Inc. (SNTA) Tops Q1 EPS by 1c

Synta Pharmaceuticals, Inc. (NASDAQ: SNTA) reported Q1 EPS of ($0.28), $0.01 better than the analyst estimate of ($0.29). No revenue was reported.

“The final results from the GALAXY-1 study in non-small cell lung adenocarcinoma represent a significant addition to the collection of encouraging data that our ganetespib development program has generated in multiple cancer indications and confirms the choice of the chemo-sensitive patient population for the GALAXY-2 Phase 3 trial,” said Keith Gollust, Chairman of the Executive Committee of Synta. “Our primary focus for the balance of 2014 will be to maximize the value of our development assets in a cost effective manner.”

For earnings history and earnings-related data on Synta Pharmaceuticals, Inc. (SNTA) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• SanDisk unveils long-term growth strategy at 2026 Investor Day; Shares surge 12%
• Benchmark Reiterates Buy Rating on NANO Nuclear Energy (NNE)